| Literature DB >> 35686567 |
Milagros Muñoz-Chimeno1, Silvia Bartúren1, Maira Alejandra García-Lugo1, Lucia Morago1, Álvaro Rodríguez1, Juan Carlos Galán2,3, Alfredo Pérez-Rivilla4, Mercedes Rodríguez5, Rosario Millán6, Manuel Del Álamo7, Roberto Alonso8, Laura Molina9, Aitziber Aguinaga10, Ana Avellón1,3.
Abstract
BackgroundHepatitis E virus genotype 3 (HEV-3) is widely distributed throughout Europe, with incidence of infections increasing in many countries. Belgium, Bulgaria, France, Germany, Italy, the Netherlands and the United Kingdom have reported the distribution of HEV-3 subtypes in cohorts of patients with hepatic disease.AimTo describe the distribution of the HEV-3 subtypes in Spain at national and autonomous community (AC) levels between 2009 and 2019. The study was also extended to Andorra.MethodsOf 5,197 samples received by the National Reference Laboratory during the study, 409 were HEV-RNA-positive. Among these, 294 (71.9%) were further typed based on an ORF2 sequence fragment, or, for a subset of 74, based on the full-coding genome sequence.ResultsHEV-3 was detected in 291 samples. The dominant subtype in Spain was HEV-3f (88.3%; 257/291), which occurred in all ACs, with no change in detection level over time. Within this subtype, three subclusters were characterised: HEV-3f-B, HEV-3f-A1 and HEV-3f-A2. The second most common HEV subtype was the recently described HEV-3m (7%; 21/291), with two subclusters identified: HEV-3m-A, which has been known since 2010, and HEV-3m-B, since 2014. The third most encountered subtype was HEV-3c (4.1%; 12/291), with a frequency not increasing over time, unlike observations in some European countries.ConclusionThe importance of the surveillance of HEV-3 subtype and subcluster circulation is yet to be assessed. This surveillance together with the comprehensive epidemiological characterisation of clinical cases, could support the identification of sources of transmission and the establishment of control measures nationally and internationally.Entities:
Keywords: HEV; Hepatitis E; Spain; genotype 3; subtype
Mesh:
Substances:
Year: 2022 PMID: 35686567 PMCID: PMC9198656 DOI: 10.2807/1560-7917.ES.2022.27.23.2100542
Source DB: PubMed Journal: Euro Surveill ISSN: 1025-496X
Figure 1Phylogenetic analysis, using HEV genotype- and subtype-reference sequences, of 74 full-coding genome sequences of HEV-3 from Spain, 2009–2019 (n = 100 total sequences in the tree)
Figure 2(A) Phylogenetic and (B) p-genetic distance investigations of HEV-3 subtype f subclusters found among full-coding genome sequences recovered from different countries, 2013–2019 (n = 181 sequences)
Figure 3Phylogenetic analysis of 294 ORF2 fragment genetic sequences of HEV recovered in Spain, including two sequences of Andorra, 2013–2019 (n = 323 sequences in the tree)
Temporal distribution of samples testing positive for HEV-3 according to subtype and subcluster, Spain, 2009–2019 (n = 291 samples)
| Subtype | Year | Total | Periods | p value | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | n | % | 2009–2013 | 2014–2019 | ||||
| n | % | n | % | |||||||||||||||
| HEV-3abjk | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0.3 | 0 | 0.0 | 1 | 0.4 | NA |
| HEV-3c | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 2 | 0 | 4 | 3 | 12 | 4.1 | 3 | 7.5 | 9 | 3.6 | 0.25 |
| HEV-3f | 1 | 3 | 11 | 12 | 7 | 30 | 17 | 32 | 46 | 52 | 46 | 257 | 88.3 | 34 | 85.0 | 223 | 88.8 | 0.48 |
| HEV-3f A1 | 1 | 1 | 10 | 12 | 6 | 19 | 11 | 26 | 38 | 48 | 41 | 213 | 73.2 | 30 | 75.0 | 183 | 72.9 | 0.78 |
| HEV-3f A2 | 0 | 2 | 1 | 0 | 1 | 11 | 6 | 6 | 7 | 4 | 4 | 42 | 14.4 | 4 | 10.0 | 38 | 15.1 | 0.39 |
| HEV-3f B | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 2 | 0.7 | 0 | 0.0 | 2 | 0.8 | NA |
| HEV-3m | 0 | 1 | 1 | 1 | 0 | 3 | 3 | 3 | 5 | 3 | 1 | 21 | 7.2 | 3 | 7.5 | 18 | 7.2 | 0.94 |
| HEV-3m A | 0 | 1 | 1 | 1 | 0 | 1 | 3 | 0 | 2 | 1 | 1 | 11 | 3.8 | 3 | 7.5 | 8 | 3.2 | 0.18 |
| HEV-3m B | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 3 | 3 | 2 | 0 | 10 | 3.4 | 0 | 0.0 | 10 | 4.0 | NA |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
HEV-3: hepatitis virus genotype 3; NA: not applicable.
HEV-3 subtype distribution in different geographical areas, Spain and Andorra, 2009–2019 (n = 289 samples)a
| Subtype | Spanish autonomous communitiesb | AD | Total | Geographical groups | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CM | CL | MD | EX | AR | IB | CT | VC | MC | AS | CB | NC | GA | RI | PV | AN | CN | ||||||||||||
| Centrec | Eastd | Northe | Southf | |||||||||||||||||||||||||
| n | % | n | % | n | % | n | % | n | % | |||||||||||||||||||
| HEV-3abj | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0.3 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 1 | 3.8 |
| HEV-3c | 0 | 1 | 5 | 0 | 0 | 1 | 1 | 2 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 12 | 4.2 | 6 | 4.0 | 4 | 12.9 | 1 | 1.2 | 1 | 3.8 |
| HEV-3f | 8 | 8 | 109 | 5 | 2 | 3 | 7 | 9 | 4 | 20 | 5 | 14 | 12 | 2 | 22 | 21 | 2 | 2 | 255 | 88.2 | 130 | 86.1 | 27 | 87.1 | 75 | 92.6 | 23 | 88.5 |
| HEV-3f-A1 | 6 | 7 | 85 | 4 | 1 | 2 | 7 | 8 | 4 | 18 | 4 | 13 | 12 | 1 | 19 | 17 | 2 | 1 | 211 | 73.0 | 102 | 67.5 | 23 | 74.2 | 67 | 82.7 | 19 | 73.2 |
| HEV-3f-A2 | 2 | 1 | 23 | 1 | 1 | 1 | 0 | 1 | 0 | 2 | 0 | 1 | 0 | 1 | 3 | 4 | 0 | 1 | 42 | 14.5 | 27 | 17.9 | 4 | 12.9 | 7 | 8.7 | 4 | 15.4 |
| HEV-3f-B | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0.7 | 1 | 0.7 | 0 | 0.0 | 1 | 1.2 | 0 | 0.0 |
| HEV-3m | 1 | 2 | 11 | 1 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 2 | 0 | 0 | 0 | 1 | 0 | 0 | 21 | 7.3 | 15 | 9.9 | 0 | 0.0 | 5 | 6.2 | 1 | 3.8 |
| HEV-3m-A | 1 | 2 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 2 | 0 | 0 | 0 | 1 | 0 | 0 | 11 | 3.8 | 6 | 4.0 | 0 | 0.0 | 4 | 4.9 | 1 | 3.8 |
| HEV-3m-B | 0 | 0 | 8 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10 | 3.5 | 9 | 5.9 | 0 | 0.0 | 1 | 1.2 | 0 | 0.0 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
AD: Andorra.
Among 291 samples positive for HEV-3, 289 were accompanied by data on the autonomous community where the patient was located.
b AN: Andalusia; AR: Aragon; AS: Principality of Asturias; CB: Cantabria; CL: Castile and León; CM: Castile-La Mancha; CN: Canary Islands; CT: Catalonia; EX: Extremadura; GA: Galicia; HEV-3: hepatitis virus genotype 3; IB: Balearic Islands; MC: Region of Murcia; MD: Community of Madrid; NC: Chartered Community of Navarre; PV: Basque Country; RI: La Rioja; VC: Valencian Community.
c Centre: CM, CL, MD and EX.
d East: AR, IB, CT, VC and MC. AD data were also included in the ‘East’ group as this country locates to the east of Spain.
e North: AS, CB, NC, GA, RI and PV.
f South: AN and CN.
Figure 4(a) Geographical distribution of samples testing positive for hepatitis E virus genotype 3 according to subtype and (b) temporal distribution with further stratification of subtypes at the subcluster level, Spain and Andorra, 2009–2019 (n = 289 samples)a